Canaccord analyst John Young upgraded STAAR Surgical (NASDAQ: STAA) from Hold to Buy with a price target of $27.00 (from $22.00).

The analyst comments: "STAAR Surgical announced preliminary Q1/26 revenue of >$90M – well above our $60.5M estimate and consensus of $67.6M, likely benefitting to a certain degree from restocking post termination of merger with Alcon. As a reminder, the company is currently not providing guidance to investors. This compares to $42.6M of revenue in Q1/25, which saw the impact from excess inventory in the company’s China channel. $90M of revenue would imply Y/Y growth of 111% and Q/Q growth of 56%. The press release noted that China accounted for the majority of the increase in net sales, along with continued double-digit growth in the Americas. While specific EBITDA was not given, the company noted that it expects a meaningful improvement in adjusted EBITDA in Q1/26. The company’s business in the Middle East and other parts of EMEA and APAC were negatively affected by significant geopolitical and macroeconomic challenges, leading to a decline in sales. STAAR intends to report full Q1 results in early May."

For an analyst ratings summary and ratings history on STAAR Surgical click here. For more ratings news on STAAR Surgical click here.

Shares of STAAR Surgical closed at $20.88 yesterday.